PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
131.08%
Revenue growth 1.25-1.5x CSIQ's 89.20%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
51.20%
Gross profit growth at 50-75% of CSIQ's 89.20%. Martin Whitman would question if cost structure or brand is lagging.
No Data
No Data available this quarter, please select a different quarter.
55.54%
Operating income growth under 50% of CSIQ's 184.47%. Michael Burry would be concerned about deeper cost or sales issues.
14.86%
Net income growth under 50% of CSIQ's 161.14%. Michael Burry would suspect the firm is falling well behind a key competitor.
-1378.57%
Negative EPS growth while CSIQ is at 160.45%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-1378.57%
Negative diluted EPS growth while CSIQ is at 160.45%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-94.15%
Share reduction while CSIQ is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-94.15%
Reduced diluted shares while CSIQ is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-1171.14%
Negative OCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.97%
Negative FCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.32%
Our R&D shrinks while CSIQ invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
No Data
No Data available this quarter, please select a different quarter.